Traders sold shares of Johnson & Johnson (NYSE: JNJ). $ 147.46 million flowed into the stock and $ 266.11 million flowed out of the stock on the tick-down, $ 118.65 million out of the stock. Of all equities tracked, Johnson & Johnson had the highest net out-flow for the day. Johnson & Johnson traded up $ 0.97 for the day and closed at $ 145.76
A number of research firms recently commented on JNJ. Wells Fargo & Co reiterated an “outperform” rating and set a $ 160.00 price objective (up from 155.00) on Johnson & Johnson in a research report on Friday. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating of $ 150.89. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, January 9th. JPMorgan Chase & Co. cut Johnson & Johnson from an overweight rating to a “neutral” rating in a research report on Tuesday, January 2nd. Finally, BMO Capital Markets is quoted by Johnson & Johnson to $ 161.00 and gives the company an “outperform” rating in a research report on Tuesday, December 12th. Four equities research analysts have rated the value of the stock, they have given a hold and have issued a rating to the stock. The company has an average rating of “Hold” and an average target price of $ 145.94.
The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $ 391,590.00, a PE ratio of 25.31, a P / E / G ratio of 2.75 and a beta of 0.80.
Johnson & Johnson (NYSE: JNJ) last issued its quarterly earnings on Tuesday, October 17th. The company reported $ 1.90 EPS for the quarter, topping analysts’ consensus estimates of $ 1.80 by $ 0.10. The business had revenue of $ 19.65 billion during the quarter, compared to analysts’ expectations of $ 19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the year, the business posted $ 1.68 earnings per share. equities research analysts anticipate that Johnson & Johnson will post 7.28 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be given a dividend of $ 0.84 per share. This represents a $ 3.36 annualized dividend and a dividend yield of 2.31%. The former dividend date is Monday, February 26th. Johnson & Johnson’s dividend payout ratio is currently 58.33%.
Several large investors have recently added their stakes in the stock. Lenox Wealth Advisors Inc. grew its position in shares of Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $ 116,000 after purchasing an additional 5 shares in the last quarter. Landmark Financial Advisors LLC boosted its stake in Johnson & Johnson by 0.4% during the second quarter. Landmark Financial Advisors LLC now owns 1,962 shares of the company’s stock valued at $ 259,000 after buying an additional 7 shares during the last quarter. Paradigm Financial Advisors LLC boosted its stake in Johnson & Johnson by 0.3% during the second quarter. Paradigm Financial Advisors LLC now owns 2,649 shares of the company’s stock valued at $ 350,000 after buying an additional 9 shares during the last quarter. Premier Asset Management LLC boosted its stake in Johnson & Johnson by 0.4% during the second quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock valued at $ 363,000 after buying an additional 12 shares during the last quarter. Finally, Lbmc Investment Advisors LLC boosted its stake in Johnson & Johnson by 0.4% during the second quarter. Lbmc Investment Advisors LLC now owns 3,718 shares of the company’s stock valued at $ 492,000 after buying an additional 14 shares during the last quarter. Hedge funds and other institutional investors 65.70% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Investors Sell Shares of Johnson & Johnson (JNJ) on Strength (JNJ)” was first posted by The Ledger Gazette and is the sole property of The Ledger Gazette. If you are reading this piece of content on another publication, it has been copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://ledgergazette.com/2018/01/14/investors-sell-shares-of-johnson-johnson-jnj-on-strength-jnj.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily – concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies MarketBeat.com’s FREE daily email newsletter .